{{Rsnum
|rsid=2230949
|Gene=IGF2
|Chromosome=11
|position=2132958
|Orientation=plus
|GMAF=0.04867
|Gene_s=IGF2,SIT1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{PharmGKB
|RSID=rs2230949
|Name_s=rs2230949 C/T IGF2
|Gene_s=IGF2, INS-IGF2, IGF2AS
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: Not specified. Phenotype: This SNP was associated with clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): p = 0.0043 (ANOVA); p = 0.0261 (QMIS); p = 0.0622 (KW) Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291798
}}

{{PMID|18562769|OA=1
}} Genetic variation in insulin-like growth factors and brain tumor risk.

{{PMID|19936258|OA=1
}} Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2230949
|overall_frequency_n=683
|overall_frequency_d=10680
|overall_frequency=0.0639513
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=10
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}